Cohance Lifesciences Releases Integrated Annual Report FY25-26 and AGM Notice
Cohance Lifesciences has released its Integrated Annual Report for FY25-26, including the BRSR and AGM notice. The company reported consolidated revenue of ₹22.68 billion and adjusted EBITDA of ₹4.8 billion for FY26. Two customer molecules have entered commercial supply, with two more expected soon.
The release of the annual report and AGM notice provides important information to shareholders and the market regarding the company's financial performance, strategic direction, and governance. The details on financial results, platform development, and commercial progress have a medium-term impact on investor understanding and valuation.
The announcement is a routine release of the annual report and AGM notice, providing a comprehensive update on the company's performance and strategic initiatives. While it details positive financial results and progress in key platforms, it is presented in a factual and informative manner.
Cohance Lifesciences Limited has announced the release of its Integrated Annual Report for the Financial Year 2025-26, along with the Business Responsibility and Sustainability Report (BRSR) and the Notice of the 8th Annual General Meeting (AGM).
The Integrated Annual Report, prepared in accordance with the principles of the International Framework issued by the IFRS Foundation, details the company's strategy, governance, risks, performance, and future outlook. It adopts a multi-capital approach, illustrating how the company utilizes and transforms Financial, Manufactured, Intellectual, Human, Social & Relationship, and Natural Capital. The report is also aligned with SEBI's BRSR framework and the UN Sustainable Development Goals.
The company has made significant progress in its integrated ADC and Oligonucleotide platforms. For the fiscal year 2025-26, Cohance reported consolidated revenue of ₹22.68 billion and adjusted EBITDA of ₹4.8 billion, with a consolidated margin of 21%. Gross margin improved to 70.8% year-on-year. The company also highlighted its commitment to quality, safety, and sustainability, retaining its EcoVadis Gold rating and achieving reductions in emissions, freshwater consumption, and waste generation. Investments are planned for ADC expansion and operationalization of the oligonucleotide facility.
The report also mentions that two customer molecules from the Phase III pipeline have entered commercial supply, with two more expected within 12-18 months. One of these molecules has received US FDA approval. The company's integrated approach aims to support complex therapeutic modalities from development through commercial supply.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under annual results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.